Admissions to Substance Abuse Treatment for the Abuse of Opioid Analgesics: Findings from the Treatm

1
Admissions to Substance Abuse Treatment for the
Abuse of Opioid AnalgesicsFindings from the
Treatment Episode Data Set

• Deborah Trunzo
• Office of Applied Studies
• Substance Abuse and Mental Health Services
  Administration
• May 5, 2008

2
Treatment Episode Data Set (TEDS)

• Client-level information on treatment admissions
• Collected by States and reported to SAMHSA
• Primarily from facilities receiving public funds
• Estimated coverage 80
• 1.8 million admissions annually

3
TEDS Data Elements

• Demographic variables
• Drug use history
• top 3 substances of abuse at admission
• route of administration
• frequency of use
• age at first use
• Treatment variables

4
Limitations of TEDS

• Drugs of abuse reported in generic categories,
  not specific brand names or formulations
• All States report on opiates other than heroin
  as a group
• Only 16 States report on specific opioid
  analgesics

5
Treatment Admissions by Primary Substance 2006
N 1.8 million
Includes admissions where primary substance was
reported as Other opiates/synthetics. Excludes
admissions for non-prescription use of methadone.
6
Treatment Admissions Involving Opioid
Analgesics11992-2006
OxyContin introduced
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
7
Percent Increase in Admissions for Heroin and
Opioid Analgesics1 1997-2006
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
8
Admissions Involving Specific Opioid Analgesics1
2006
1Data submitted by 16 States AL, HI, ID, KY, MD,
ME, MO, MS, ND, NH, NJ, NM, NV, NY, OH, SD
9
States Reporting Specific Opioid Analgesics 2006
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
10
Percent Increase in Admissions for Specific
Opioid Analgesics12000-2006
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone. Analysis
restricted to 13 States that reported detailed
drug codes for 2000 and 2006.
11
Opioid Analgesic1 Admission Rates by State 2006
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
12
Opioid Analgesic1 Treatment Admission Rates by
Urbanization 2000 and 2006
MSA Metropolitan Statistical Area
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
13
Percent of Primary and Secondary Opioid Analgesic
Admissions Using Other Substances 2006
14
Treatment Admissions Involving Opioid Analgesics1
by Age and Route of Administration 2006
Oral
Inhaled
Injected
Other
Age
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
15
Treatment Admissions Involving Oxycodone1 by Age
and Route of Administration 2006
Oral
Injected
Inhaled
Other
Age
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Oxycodone.
16
Characteristics of Opioid Analgesic1
Admissions1997 and 2006
1 Includes admissions where primary, secondary,
or tertiary substance was reported as Other
opiates/synthetics. Excludes admissions for
non-prescription use of methadone.
17
Admissions for Primary Opioid Analgesics1 by Age
of First Use 1997-2006
55
45 - 54
35 - 44
25 - 34
18 - 24
17 and under
Includes admissions where primary substance was
reported as Other opiates/synthetics. Excludes
admissions for non-prescription use of methadone.